What is the management for diabetic ketoacidosis (DKA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Diabetic Ketoacidosis (DKA)

The management of diabetic ketoacidosis requires aggressive fluid resuscitation, insulin therapy, electrolyte replacement, and identification and treatment of underlying causes, following a structured protocol that includes hourly monitoring of vital signs, neurological status, blood glucose, and fluid input/output. 1

Diagnosis and Classification

DKA is diagnosed based on:

  • Blood glucose >250 mg/dL (although euglycemic DKA can occur)
  • Arterial pH <7.3
  • Bicarbonate <15 mEq/L
  • Moderate ketonemia or ketonuria 1

Severity classification:

Parameter Mild Moderate Severe
Arterial pH 7.25-7.30 7.00-7.24 <7.00
Bicarbonate (mEq/L) 15-18 10-14 <10
Mental Status Alert Alert/drowsy Stupor/coma

Treatment Protocol

1. Fluid Therapy

  • Initial fluid resuscitation with isotonic saline at 15-20 ml/kg/hour for the first hour 1
  • Continue with balanced crystalloids (e.g., Lactated Ringer's solution) at 4-14 ml/kg/hour based on hydration status 1
  • Monitor corrected sodium levels using formula: Measured sodium + 1.6 × [(glucose mg/dl - 100)/100] 1

2. Insulin Therapy

  • Start insulin after initial fluid resuscitation 1
  • Regular insulin by continuous IV infusion at 0.1 units/kg/hour (no initial bolus) 1
  • Continue insulin infusion until resolution of metabolic acidosis 1
  • For patients with uncomplicated DKA, subcutaneous rapid-acting insulin analogs may be used in emergency departments or step-down units 2

3. Electrolyte Replacement

  • Potassium: Begin replacement when serum K+ <5.5 mEq/L and adequate urine output is confirmed 1
    • Add 20-30 mEq/L potassium to IV fluids (2/3 KCl and 1/3 KPO4) 1
  • Phosphate: Generally included in replacement as KPO4, especially with severe hypophosphatemia 1
  • Bicarbonate: Generally not recommended for DKA treatment 2

4. Monitoring

  • Hourly: Vital signs, neurological status, blood glucose, fluid input/output 1
  • Every 2-4 hours: Electrolytes, BUN, creatinine, venous pH 1
  • Monitor for complications: cerebral edema, hypoglycemia, hypokalemia, fluid overload 1

5. Transition from IV to Subcutaneous Insulin

  • Administer basal insulin 2-4 hours before discontinuing IV insulin to prevent rebound hyperglycemia 2, 1
  • Consider low-dose basal insulin analog in addition to IV insulin to prevent rebound hyperglycemia 1

6. Resolution Criteria

DKA is considered resolved when:

  • Glucose levels <200 mg/dL
  • Serum bicarbonate ≥18 mEq/L
  • Venous pH >7.3 1

Complications and Prevention

Common Complications

  • Cerebral edema (rare but potentially fatal, especially in children)
  • Hypoglycemia due to excessive insulin treatment
  • Hypokalemia (occurs in approximately 50% of cases during treatment)
  • Hyperglycemic rebound due to abrupt interruption of IV insulin 1

Prevention Strategies

  • Avoid too rapid correction of serum osmolality (not exceeding 3 mOsm/kg/h)
  • Limit initial vascular expansion in pediatric patients
  • Perform hourly glucose monitoring during insulin infusion 1

Discharge Planning and Follow-up

  • Identify and treat underlying causes of DKA (infection, missed insulin, new diabetes diagnosis) 1
  • Provide education on diabetes self-management, glucose monitoring, and when to seek medical attention 1
  • Review medication regimen, especially insulin administration 1
  • Schedule follow-up appointment prior to discharge 1
  • Include education on sick-day management and the importance of never suspending insulin 1

Special Considerations

  • Euglycemic DKA should be treated with the same principles as classic DKA, with the addition of dextrose-containing fluids to prevent hypoglycemia 1
  • SGLT2 inhibitors should be discontinued 3-4 days before surgery to prevent DKA 2
  • Alternative protocols may be considered in resource-limited settings, but the core principles of fluid resuscitation, insulin therapy, and electrolyte management remain essential 3

References

Guideline

Diabetic Ketoacidosis Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.